Absorb Bioresorbable Vascular Scaffold is Associated with Low Wall Shear Stress Compared to Xience V: A Biomechanical Analysis of the Absorb III Imaging Study.
Main Authors: Arnav Kumar1; Bill D Gogas1; Elizabeth W Thompson1; Grady Murphy Burnett1; David Molony1; Hossein Hosseini1; Karthic Chandran1; Adrien Lefieux1; Yasuhiro Honda2; Joo Myung Lee1; Patrick W Serruys3; Dean J Kereiakes4; Gregg W Stone5; Habib Samady6;
Collaborators: Mohamad Raad6; Sonu Gupta1; David G Sternheim1; Kozo Okada7; Richard J Rapoza8; Charles A Simonton8; Don P Giddens9; Alessandro Veneziani10; Spencer B King III6; Stephen G Ellis11;
1. Andreas Gruentzig Cardiovascular Center, Emory University School of Medicine, Atlanta, GA. 2. Stanford Cardiovascular Institute, Stanford, CA 3. Imperial College, London, UK. 4. The Christ Hospital Heart and Vascular Center, Cincinnati, Ohio 5. Columbia University Medical Center, New York, NY 6. Andreas Gruentzig Cardiovascular Center, Emory University School of Medicine, Atlanta, GA, United States 7. Division of Cardiovascular Medicine, Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 8. Abbott Vascular, Inc, Santa Clara, CA 9. Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA 10. Department of Mathematics and Computer Science, Emory University, Atlanta, GA 11. Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com
The Absorb bioresorbable vascular scaffold (BVS) has higher rates of target lesion failure (TLF) at 3 years. Low WSS promotes several mechanisms related to device TLF. In the ABSORB III Imaging study, a greater proportion of vessels treated with BVS compared to XV demonstrated low WSS [BVS: 22% vs XV: 6%, p<0.029]. Compared to XV, BVS demonstrated lower circumferential WSS (1.73 vs 2.21 Pa; p=0.036). Patients who received BVS were 4.8 more likely to demonstrate low WSS across the scaffold/stent when compared to XV. BVS was also independently associated with greater area of low WSS (Beta:0.251, p = 0.002).